➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Merck
Baxter
Medtronic
Colorcon

Last Updated: July 7, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020327


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

NDA 020327 describes ISOVUE-370, which is a drug marketed by Bracco and is included in two NDAs. It is available from one supplier. Additional details are available on the ISOVUE-370 profile page.

The generic ingredient in ISOVUE-370 is iopamidol. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the iopamidol profile page.
Summary for 020327
Tradename:ISOVUE-370
Applicant:Bracco
Ingredient:iopamidol
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020327
Mechanism of ActionX-Ray Contrast Activity
Medical Subject Heading (MeSH) Categories for 020327
Suppliers and Packaging for NDA: 020327
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ISOVUE-200 iopamidol INJECTABLE;INJECTION 020327 NDA Bracco Diagnostics Inc 0270-1315 0270-1315-45 10 BOTTLE in 1 BOX (0270-1315-45) > 200 mL in 1 BOTTLE
ISOVUE-200 iopamidol INJECTABLE;INJECTION 020327 NDA Bracco Diagnostics Inc 0270-1315 0270-1315-95 6 BOTTLE in 1 BOX (0270-1315-95) > 500 mL in 1 BOTTLE

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength41%
Approval Date:Oct 12, 1994TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength51%
Approval Date:Oct 12, 1994TE:RLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength61%
Approval Date:Oct 12, 1994TE:RLD:Yes

Expired US Patents for NDA 020327

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bracco ISOVUE-200 iopamidol INJECTABLE;INJECTION 020327-001 Oct 12, 1994   Start Trial   Start Trial
Bracco ISOVUE-370 iopamidol INJECTABLE;INJECTION 020327-004 Oct 12, 1994   Start Trial   Start Trial
Bracco ISOVUE-300 iopamidol INJECTABLE;INJECTION 020327-003 Oct 12, 1994   Start Trial   Start Trial
Bracco ISOVUE-250 iopamidol INJECTABLE;INJECTION 020327-002 Oct 12, 1994   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Johnson and Johnson
Moodys
Dow
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.